ACIP

June 2022

ACIP approved the following recommendations by majority vote at its June 22-23, 2022 meeting:

• ACIP recommends that adults aged ≥65 years preferentially receive one of the following influenza vaccines: quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (aIIV4).  If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.
• Affirm the updated MMWR Recommendations and Reports, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022-23 Influenza Season.”
• PCV15 (15-valent pneumococcal conjugate vaccine) may be used as an option to PCV13 (13-valent pneumococcal conjugate vaccine) for children aged <19 years according to currently recommended PCV13 dosing and schedules.
• MMR vaccine (Priorix, GSK) according to currently recommended schedules and off-label uses as an option to prevent measles, mumps, and rubella.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.